Navigation Links
Protein may be key to new treatment in a childhood cancer
Date:2/7/2011

ma cells to die. Among those kinases, cell checkpoint kinase 1 (CHK1) had the strongest effect. "This screen was an unbiased study," said Cole. "We did not know beforehand which kinase would have the most potent effect. In fact, we would not have suspected CHK1, which was thought to be a tumor suppressor. It actually has the opposite effect in neuroblastoma. Its signals appear to drive neuroblastoma growth, likely by allowing them to tolerate stress to DNA caused by the MYC and MCYN oncogenes, which are active in neuroblastoma. Blocking CHK1 activity by RNA interference or by small-molecule inhibitors kills neuroblastoma cells."

When cancer cells are treated with chemotherapy, they can repair themselves though CHK1 signaling, making the chemotherapy less effective. Normal cells have redundant repair pathways and are not affected by CHK1 inhibition. Therefore CHK1 inhibitors are already being tested in adult clinical trials, in combination with chemotherapy, as a possible treatment for lung cancer, pancreatic cancer and other solid tumors. The current study suggests that neuroblastoma cells are particularly sensitive to CHK1 inhibition, without being combined with other agents.

CHK1 is not the first kinase with an important role in neuroblastoma. Some of the collaborators in this study from The Children's Hospital of Philadelphia previously discovered that the anaplastic lymphoma kinase gene (ALK), which carries the code for the ALK kinase, gives rise to some high-risk forms of neuroblastoma. Children's Hospital is currently testing ALK inhibitors in pediatric clinical trials of neuroblastoma, under the sponsorship of the Children's Oncology Group, a cooperative multicenter research organization.

"While it is compelling that there is single-agent activity in neuroblastoma," said Cole. "we anticipate that CHK1 inhibitors combined with chemotherapy will be significantly more potent." Cole expects pediatric oncologists to begin testing CHK1 i
'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New and Delicious, Almond Butter Filled, Cookie Bites With 35.7% Protein to Help Manage Weight and Build Muscle
2. Research highlights role of protein pair in obesity regulation
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Smithfield, United Food and Commercial Workers Union, and Food Networks Paula Deen to Deliver 150,000 Servings of Protein to San Francisco Food Bank
5. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
6. Protein Appears Key to Intestinal Balance
7. SIBLING proteins may predict oral cancer
8. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
9. Cells of aggressive leukemia hijack normal protein to grow
10. Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants
11. Proteins May Predict Spread of Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Atlantic Spine Center , a ... three locations in New Jersey, announces the opening of ... facility is at 1045 Park Avenue (at East 86th ... can be arranged by calling 1-844-912-2406. , Dr. ... Center, has been a pioneer in the development of ...
(Date:6/2/2015)... June 02, 2015 SB 277 (CA ... for children to attend public or private school. SB277 ... but bypassed the Appropriations Committee (Sacramento Bee, May 11, ... contentious hearings. , “We believe that this bill ... (PBEs) more than it will (the) affect public health ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into its VIP Woman of the ... for leadership in business. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Job satisfaction is essential ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Woman of the Year ... leadership in life coaching. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Her work as a ...
Breaking Medicine News(10 mins):Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2
... Pharmacologic Data Presented at American Association for Cancer Research,s ... DENVER, April 21 Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced the presentation of final data from a ... picoplatin in patients with solid tumors. Results showed that ...
... April 21 Bio-Optronics, Inc. will enhance ... with click-through integration to Interspond,s RxPaying(TM) debit ... payment alternative which improves efficiency and increases ... points in clinical trial workflow into which ...
... Scenic ride and summer weekend fun ahead in Gladstone GLADSTONE, ... Cross is teaming up with several area groups and businesses to ... with the first annual "Da, U.P. Ride for the Red" on ... Friday, July 17, local food vendors will offer their fares. Beer ...
... clopidogrel can be prescribed to patients with acute ischaemia ... (ASA). The Institute for Quality and Efficiency in Health ... clopidogrel and ASA actually has a higher benefit for ... published on 31 March 2009, concludes that combination therapy ...
... April 21 More people are turning to ... their medical condition - tattooing. A case ... the American Association of Clinical Endocrinologists (AACE) 18th ... this new phenomenon, while urging discussion from the ...
... 21 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) fiscal ... 2009. You are invited to participate in a webcast the ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Second ... released to the public after the NYSE close on Monday, May ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS) 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 3Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 4Health News:New Research Reveals Need for Doctors to Know About Medical Tattoos 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
(Date:6/1/2015)... 1, 2015 NEOVIA ONCOLOGY Ltd. ... the development and commercialization of novel, multi-function drugs ... met with the U.S. Food and Drug Administration ... an Investigational New Drug (IND) application for its ... of the meeting, Neovia has clarified details of ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3Neovia Oncology Announces First IND Meeting 2
... Feb.5 Cytopia Limited (ASX: CYT) has successfully ... for CYT997, the company,s anticancer vascular-disrupting agent (VDA). ... study have been achieved. These were to determine ... toxicities (DLTs) for the agent when administered orally ...
... (OTCBB: ORMP.OB), a developer of alternative drug,delivery systems, ... of concept,study in South Africa of insulin suppositories, ... for two visits, with,two different formulations. , ... insulin absorption and reactive,glucose lowering effect. The suppositories ...
Cached Medicine Technology:Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 2Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 3Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 4Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... An indirect immunofluorescence antibody test ... anti-neutrophil cytoplasmic antibodies (ANCA) in human ... sera of patients with necrotizing vasculitides ... to the clinical and other laboratory ...
Medicine Products: